Apellis Pharmaceuticals Inc (NASDAQ: APLS) on Friday, plunged -3.27% from the previous trading day, before settling in for the closing price of $26.00. Within the past 52 weeks, APLS’s price has moved between $24.34 and $70.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 91.42% over the past five years. The company achieved an average annual earnings per share of 35.47%. With a float of $103.54 million, this company’s outstanding shares have now reached $124.50 million.
Let’s look at the performance matrix of the company that is accounted for 710 employees. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 100.32%. The most recent insider transaction that took place on Feb 11 ’25, was worth 10,360. In this transaction Chief Business & Strat Officer of this company sold 363 shares at a rate of $28.54, taking the stock ownership to the 83,945 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Officer proposed sale 363 for $28.54, making the entire transaction worth $10,360.
Apellis Pharmaceuticals Inc (APLS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.47% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Apellis Pharmaceuticals Inc (APLS) is currently performing well based on its current performance indicators. A quick ratio of 3.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach 0.13 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (NASDAQ: APLS) saw its 5-day average volume 2.11 million, a positive change from its year-to-date volume of 1.79 million. As of the previous 9 days, the stock’s Stochastic %D was 11.18%. Additionally, its Average True Range was 1.31.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 7.20%, which indicates a significant decrease from 15.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.32% in the past 14 days, which was lower than the 53.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.14, while its 200-day Moving Average is $33.95. Nevertheless, the first resistance level for the watch stands at $26.02 in the near term. At $26.90, the stock is likely to face the second major resistance level. The third major resistance level sits at $27.74. If the price goes on to break the first support level at $24.30, it is likely to go to the next support level at $23.46. The third support level lies at $22.58 if the price breaches the second support level.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
Market capitalization of the company is 3.13 billion based on 124,393K outstanding shares. Right now, sales total 396,590 K and income totals -528,630 K. The company made 196,830 K in profit during its latest quarter, and -57,450 K in sales during its previous quarter.
